BioCentury | May 5, 2003
Product Development

The EPO crowd in Europe

...and has a discovery pipeline that includes PLD-117, a peptide with TPO-like activity licensed from Receptron Inc....
BioCentury | Jan 14, 2002
Product Development

TPO through 3-D glasses

...hoping to harness the potential of TPO mimetic peptides to treat thrombocytopenia induced by chemotherapy. Receptron Inc....
BioCentury | Apr 9, 2001
Clinical News

RCN-01303: Began Phase I trial

...activity enhancer Indication: Treat thrombocytopenia due to chemotherapy End point: Safety and platelet count Status: Receptron...
BioCentury | Jun 28, 1999
Clinical News

Receptron preclinical data

...EPO-R by ERP was unexpected since the receptor is thought to require dimerization for activation. Receptron Inc....
Items per page:
1 - 4 of 4
BioCentury | May 5, 2003
Product Development

The EPO crowd in Europe

...and has a discovery pipeline that includes PLD-117, a peptide with TPO-like activity licensed from Receptron Inc....
BioCentury | Jan 14, 2002
Product Development

TPO through 3-D glasses

...hoping to harness the potential of TPO mimetic peptides to treat thrombocytopenia induced by chemotherapy. Receptron Inc....
BioCentury | Apr 9, 2001
Clinical News

RCN-01303: Began Phase I trial

...activity enhancer Indication: Treat thrombocytopenia due to chemotherapy End point: Safety and platelet count Status: Receptron...
BioCentury | Jun 28, 1999
Clinical News

Receptron preclinical data

...EPO-R by ERP was unexpected since the receptor is thought to require dimerization for activation. Receptron Inc....
Items per page:
1 - 4 of 4